Illumina Beats the Street By a Bunch. Then Lowers By a Bunch
November 8, 2019
Illumina (ILMN) beat the street last qtr, then lowered guidance, and in the meantime ILMN is stuck in a basing pattern.
Research Reports
Illumina Drops After Missing Estimates, Lowering Guidance
August 8, 2019
Illumina (ILMN) got crushed after the company missed profit estimates and lowered guidance dramatically.
Illumina Advances Healthcare Technology
June 6, 2019
Illumina (ILMN) has been on the forefront of advances in Healthcare technologies. ILMN is an investment in future opportunities.
Illumina Has Lost its Positive Momentum
March 20, 2019
Illumina (ILMN), the maker of gene sequencing systems, had a banner 2018 after it introduced its Novaseq system. Now in 2019, comparisons will be tougher.
Illumina’s P/E Looks Good, But Profit Estimates Don’t
November 30, 2018
Illumina (ILMN) often has a P/E in the high-50s or 60s, and now its around 50. This could be a time to buy, but profit growth looks to slow.
Illimina Soars as Genome Growth Continues to Grow
September 11, 2018
Shares of Illumina (ILMN) have soared from $210 to $350 as demand for genome machines and consumables continue to climb.
Illumina is Quite Pricey with a P/E of 56
June 26, 2018
Ilumina (ILMN) has gone from $175 to $270 in a year, and with a P/E of 56 the stock is quite pricey. Let’s take a quick look.
Customers Are Upgrading With Illumina
April 17, 2018
Illumina (ILMN) makes gene-sequencing machines used to analyze DNA. ILMN’s new NovaSeq machines are so good customers are upgrading.
Better Profits Expected for Illumina in 2018
December 19, 2017
Illumina (ILMN) is expected to have accelerating profit growth in 2018 as its new gene sequencing system is generating momentum. But is the good news priced into ILMN stock?
Illumina Breaks Out On Strong NovaSeq Demand
September 12, 2017
Shares of Illumina (ILMN) broke out and went into All-Time high territory after the company said demand for its new NovaSeq machine has been solid.
Illumina Is In Need of Some Upgrades
July 18, 2017
Illumina (ILMN) is in need of upgrades. Not analyst upgrades, customer upgrades. ILMN’s NovaSeq is superior to its HiSeqX machines, but costs to upgrade are high.
NovaSeq Marks an Inflection Point for Illumina
March 5, 2017
Illumina’s (ILMN) popped after announcing its new system NovaSeq which will take the cost of a genome from $1000 to $100 someday.
Illumina’s Number Continue to Deteriorate as the Stock Sags
November 23, 2016
Illumina (ILMN) has had its issues lately, but with great growth opportunity with the future of gene sequencing, is this a stock to buy now?
Illumina Stock Bounces Back, But Profit Growth is Still Slow
September 22, 2016
Shares of Illumina (ILMN) have made a solid move higher — from $135 to $175 — but profit growth still isn’t what it used to be.
Has Illumina Lost its Magic Touch?
July 1, 2016
Illumina (ILMN) used to be a stock market darling. But now that the stock is down more than 40%, is this a good time to buy?
A Rare Buying Opportunity
November 7, 2015
Illumina (ILMN) is at a rare buying opportunity, but with profit growth looking weak the next two qtrs the stock may sit here a while.
Slowing Growth, High P/E
July 29, 2015
Illumina (ILMN) , the king of gene sequencing machines, has a high P/E and slowing profit growth ahead.
The Games Illumina Plays
December 10, 2014
Illumina’s (ILMN) new gene sequencing system should make profits explode, but ILMN management isn’t admitting the truth.
Still REALLY HIGH
May 19, 2014
Illuumina (ILMN) has come down a little bit but the stock is still REALLY HIGH. Here’s What I think ILMN is worth.
Gene Sequencing
February 26, 2014
Illumina (ILMN) has new revolutionary gene sequencing devices coming out, but is that reflected in ILMN’s stock price?